NYSE · Biotechnology · USD
Alto Neuroscience, Inc. (ANRO) Stock Analysis
Alto Neuroscience, Inc. (ANRO) is a Biotechnology stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ANRO Key Statistics
As of Sep 4, 2026Trading
- Open
- $36.18
- Previous Close
- $36.40
- Day's Range
- 35.45–36.98
- 52-Week Range
- 3.50–37.48
- Volume
- 269.90K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.16
Valuation
- Market Cap
- $1.40B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.26
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$63.24M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 39.24M
- 1-Year Return
- +912.82%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 546.47K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
ANRO Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +99.72% |
| 2025 | +320.80% |
| 2024 (partial year) | −79.57% |
As of September 4, 2026.
ANRO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$63.24M | — |
| 2024 | $0.00 | −$61.43M | — |
| 2023 | $0.00 | −$36.31M | — |
| 2022 | $0.00 | −$27.71M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$66.36M | −$63.24M | — |
| 2024 | $0.00 | — | −$68.61M | −$61.43M | — |
| 2023 | $0.00 | — | −$37.81M | −$36.31M | — |
| 2022 | $0.00 | — | −$27.46M | −$27.71M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ANRO Valuation vs Biotechnology Median
Median of 656 stocks| Metric | ANRO | Biotechnology median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Alto Neuroscience Promotes Nick Smith To President, CFO, Effective Aug. 26
BenzingaHC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55
BenzingaAlto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
YahooAre Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
YahooAlto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
YahooWedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26
Benzinga
All 10 articles ↓Show fewer ↑
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37
BenzingaAlto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
YahooAlto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
BenzingaAlto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B